Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications

Reinvigorating the antitumor immune response using immune checkpoint inhibitors (ICIs) has revolutionized the treatment of several malignancies. However, extended use of ICIs has resulted in a cancer-specific response. In tumors considered to be less immunogenic, the response rates were low or null....

Descripción completa

Detalles Bibliográficos
Autores principales: Wanderley, Carlos Wagner S., Correa, Tatiana Strava, Scaranti, Mariana, Cunha, Fernando Queiroz, Barroso-Sousa, Romualdo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094400/
https://www.ncbi.nlm.nih.gov/pubmed/35572596
http://dx.doi.org/10.3389/fimmu.2022.816642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094400/
https://www.ncbi.nlm.nih.gov/pubmed/35572596
http://dx.doi.org/10.3389/fimmu.2022.816642

Ejemplares similares